|
Evofem Biosciences, Inc. announced that two additional US patents which cover Phexxi (lactic acid, citric acid and potassium bitartrate) and its labelled indication are now listed in the US Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
"The Orange Book listing of these two patents covering Phexxi's composition of matter and its method of use in contraception is an important step in further strengthening our patent portfolio," said Evofem Biosciences CEO Saundra Pelletier. "We plan to further expand our intellectual property estate in the US and overseas as we continue to iterate our vaginal pH modulator platform and seek entry into global markets."
The newly listed US Patent No. 11,337,989 (the '989 patent) covers contraception using the L-Lactic Acid Phexxi formulation. The '989 patent was issued by the US Patent and Trademark Office (USPTO) on May 24, 2022 and is expected to expire in March 2033.
The newly listed US Patent No. 11,439,610 (the '610 patent) covers compositions containing L-Lactic Acid, including the Phexxi formulation. The '610 patent was issued by the USPTO on September 13, 2022 and is expected to expire in March 2033.
Evofem Biosciences, Inc., is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health.
|